YTHDF1-mediated translational activation of SETD2 suppresses aerobic glycolysis and sensitizes renal cell carcinoma to sunitinib.
Renal cell carcinoma (RCC) is a highly aggressive malignancy often characterized by metabolic rewiring and limited long-term responses to targeted therapies. In this study, we unveil a previously uncharacterized tumor-suppressive paradigm driven by the m6A reader YTHDF1. Through multi-omics integration and clinical val...